Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
MET-H82E1 | Human | Biotinylated Human HGF R / c-MET Protein, Avitag™,His Tag | ![]() |
![]() ![]() |
![]() ![]() |
MET-H5256 | Human | Human HGF R / c-MET Protein, Fc Tag (MALS verified) | ![]() |
![]() ![]() ![]() ![]() |
![]() ![]() |
MET-H5227 | Human | Human HGF R / c-MET Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
Immobilized Human HGF, His Tag (Cat. No. HGF-H52H3) at 2 μg/mL (100 μL/well) can bind Human HGF R, Fc Tag (Cat. No. MET-H5256) with a linear range of 0.6-20 ng/mL (QC tested).
The purity of Human HGF R, Fc Tag (Cat. No. MET-H5256) was more than 90% and the molecular weight of this protein is around 310-320 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Capmatinib | INC-280; INCB-028060; INCB-28060; NVP-INC280-NX; C2A374O70X,INC280,INCB028060,INCB28060 | Approved | Novartis, Incyte | TABRECTA | fda | NOVARTIS PHARM | 2020-05-06 | Non small cell lung cancer (NSCLC) | Details | |
Tepotinib hydrochloride hydrate | EMD-1214063; MSC-2156119; MSC-2156119J,EMD1214063,MSC2156119,MSC2156119J | Approved | Merck Serono | Tepotinib | 日本 | Advanced non small cell lung cancer, Metastatic non-small cell lung cancer | 默克雪兰诺 | 2020-03-25 00:00:00.0 | Non small cell lung cancer (NSCLC), Metastatic non-small cell lung cancer, Advanced non small cell lung cancer | Details |
Crizotinib | PF-02341066; PF-2341066; PF-002341066; PF-1066 | Approved | Pfizer | XALKORI | fda | Non small cell lung cancer (NSCLC) | PF PRISM CV | 2011-08-26 | Non small cell lung cancer (NSCLC), ROS1-positive non-small cell lung cancer (NSCLC) | Details |
Cabozantinib S-malate | XL-184; BMS-907351,BMS907351,XL184,XL 184,BMS 907351 | Approved | Exelixis, Ipsen, Takeda | COMETRIQ | fda | Medullary thyroid cancer (MTC) | EXELIXIS | 2012-11-29 | Renal cell carcinoma, Advanced renal cell carcinoma (RCC), Medullary thyroid cancer (MTC), Hepatocellular carcinoma (HCC) | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Merestinib | LY-2801653; 5OGS5K699E,LY2801653 | Phase Ⅱ | Lilly | Solid tumours | Details |
SAR-125844 | SAR-125844,SAR125844 | Phase Ⅱ | Sanofi | Non small cell lung cancer (NSCLC) | Details |
JNJ-38877605 | JNJ-38877605,JNJ38877605 | Phase Ⅰ | Johnson & Johnson | Solid tumours | Details |
Telisotuzumab vedotin | ABBV-399; ABT-399 | Phase Ⅱ | Abbvie | Non small cell lung cancer (NSCLC) | Details |
LDC-1267 | LDC-1267 | Preclinical | Max Planck Innovation, Lead Discovery Center | Cancer | Details |
Bozitinib | CBI-3103; CBT-101;PLB-1001;APL-101 | Phase Ⅱ | Heng Kang, CBT, Beijing Pearl Biotechnology, Crown Bioscience | Glioma, Non small cell lung cancer (NSCLC), Renal cell carcinoma, Solid tumours, Hepatocellular carcinoma (HCC) | Details |
LMV-12(HE003) | LMV-12(HE003) | Phase Ⅰ | Helioeast | Solid tumours | Details |
Golvatinib tartrate | ER-396901-08; E-7050,ER39690108,E7050 | Phase Ⅱ | Eisai, QuintilesIMS | Solid tumours, Hepatocellular carcinoma (HCC), Head and neck cancer | Details |
Sitravatinib | MG-516; MG-91516; MGCD-516 | Phase Ⅲ | Mirati Therapeutics, BeiGene | Non small cell lung cancer (NSCLC) | Details |
CBT-101 | CBT-101 | Phase Ⅰ | CBT, Beijing Pearl Biotechnology | Solid tumours | Details |
Amuvatinib | MP-470; HPK-56,MP470,HPK56 | Phase Ⅱ | Astex Pharmaceuticals | Small cell lung cancer (SCLC) | Details |
TAS-115 | TAS-115,TAS115 | Phase Ⅰ | Otsuka, Taiho Pharma | Solid tumours | Details |
SHR-A1403 | SHR-A1403,SHRA1403 | Phase Ⅰ | Jiangsu Hengrui Medicine | Solid tumours | Details |
SAIT-301 | SAIT-301 | Phase Ⅰ | Samsung Medical Center | Solid tumours | Details |
HQP8361 | APG-8361; HQP-8361; MK-8033,HQP8361 | Phase Ⅰ | Merck Sharp & Dohme, Guangzhou Shun Jian Biomedical Technology, Guangzhou Baiyunshan Mingxing Pharmaceutical | Solid tumours | Details |
MK-2461 | MK-2461 | Phase Ⅱ | Merck Sharp & Dohme | Solid tumours | Details |
Recombinant plasmid-hepatocyte growth factor | Pudk-HGF | Phase Ⅲ | Academy of Military Medical Sciences, Wuhan Guanggu Humanwell Healthcare | Peripheral arterial disease (PAD) | Details |
ABT-700 | ABT-700; h224G11; Mab224G11; Mabh224G11 | Phase Ⅰ | Pierre Fabre, Abbvie | Solid tumours | Details |
PF-04217903 | PF-4217903; PF-04217903; PF-4217903-A ,PF04217903,PF4217903 | Phase Ⅰ | Pfizer | Solid tumours | Details |
SGX-523 | SGX-523,SGX523 | Phase Ⅰ | Lilly | Solid tumours | Details |
Golvatinib/Lenvatinib | Phase Ⅱ | Eisai | Glioblastoma, Angiomas, Melanoma | Details | |
Kanitinib | CX-1003,CX1003 | Phase Ⅰ | Beijing Konruns Pharmaceutical, Guangzhou ESA Biotech | Metastatic prostate carcinoma, Gastroesophageal junction adenocarcinoma | Details |
ABN-401 | ABN-401; KDDF-201603-08 | Phase Ⅱ | Abion Inc | Solid tumours | Details |
GST-HG161 | GST-HG161 | Phase Ⅰ | WuXi AppTec, Fujian Cosunter Pharmaceutical | Hepatocellular carcinoma (HCC) | Details |
EMD-1204831 | EMD-1204831 | Phase Ⅰ | Merck Serono | Solid tumours | Details |
Altiratinib | DCC-22701; DCC-2701; DP-5164; T-678746713 | Phase Ⅰ | Deciphera | Solid tumours | Details |
Ningetinib Tosylate | CT-053-PTSA; CT-053 | Phase Ⅱ | HEC Pharm | Non small cell lung cancer (NSCLC), Hepatocellular carcinoma (HCC), Renal carcinoma | Details |
Emibetuzumab | LA-480; LY-2875358 | Phase Ⅱ | Lilly | Gastric cancer, Non small cell lung cancer (NSCLC) | Details |
QBH-196 | QBH-196 | Phase Ⅰ | Shenyang Pharmaceutical University | Gastric cancer | Details |
CM-118 | CM-118,CM118 | Phase Ⅰ | Xcovery, Shanghai Zaixin Pharmaceutical | Non small cell lung cancer (NSCLC), Malignancies | Details |
Boxitinib Hydrochloride | Phase Ⅰ | HEC Pharm | Glioma, Gastric cancer, Breast cancer, Lung cancer, Renal carcinoma | Details | |
HS-10241 | HS-10241,HS10241 | Phase Ⅰ | Hansoh Pharma | Gastric cancer, Solid tumours, Lung cancer, Liver cancer | Details |
Hepapoietin (Atlas Pharmaceuticals) | APS-1010 | Phase Ⅱ | Daiichi Sankyo, Atlas Pharma | Kidney disorders, Hepatic disorders | Details |
Volitinib | AZD-6094; HMP-504; HMPL-504; HM-5016504 | NDA Filing | Hutchison Medipharma, AstraZeneca | Non small cell lung cancer (NSCLC) | Details |
AL-2846 | AL-2846,AL2846 | Phase Ⅱ | Chiatai Tianqing (CTTQ), Nanjing Advenchen Laboratories | Glioma, Non small cell lung cancer (NSCLC), Gastric cancer, Prostate cancer, Medullary thyroid cancer (MTC), Liver cancer | Details |
AMG-208 | AMG-208,AMG208 | Phase Ⅱ | Amgen | Prostate cancer, Solid tumours | Details |
Tivantinib | ARQ-197 ,ARQ197,ARQ 197 | Phase Ⅲ | ArQule, Daiichi Sankyo, Kyowa Hakko Kirin | Non small cell lung cancer (NSCLC), Hepatocellular carcinoma (HCC) | Details |
TPX-0022 | TPX-0022 | Phase Ⅰ | Turning Point Therapeutics | Solid tumours | Details |
NP-01 (Shijiazhuang No.4 Pharmaceutical/Nanjing Nadingfei Medical Technology) | NP-01 | IND Filing | Shijiazhuang No.4 Pharmaceutical, Nanjing Nadingfei Medical Technology | Gastric cancer, Prostate cancer, Lung cancer, Liver cancer | Details |
ASLAN-002 | ASLAN-002; BMS-777607; BMS-797669 | Phase Ⅱ | Bristol-Myers Squibb, Aslan | Gastric cancer, Breast cancer | Details |
MCLA-129 | MCLA-129 | Preclinical | Merus, Betta | Solid tumours | Details |
Anti-cMet SIMPLE Antibody | ARGX-111 | Phase Ⅰ | arGEN-X | Solid tumours | Details |
Refanalin | ANG-3777; BB-3; SNV-003 | Phase Ⅲ | Angion Biomedica, sinovant | Delayed graft function | Details |
EM1-mAb DuoBody (Genmab) | Ab-957 | Preclinical | Genmab, Janssen | Autoimmune diseases | Details |
Foretinib | EXEL-2880; XL-880; GSK-1363089; GSK-089; GSK-1363089G | Phase Ⅱ | Exelixis | Non small cell lung cancer (NSCLC), Breast cancer | Details |
LY-3164530 | LY-3164530 | Phase Ⅰ | Lilly | Solid tumours | Details |
Alirinetide | GM-6; GM-600; GM-602; GM-603; GM-604; GM-605; GM-606; GM-607; GM-608; GM-609 | Phase Ⅱ | Genervon | Amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), Ischemic stroke | Details |
DBPR-114 | Phase Ⅰ | National Health Research Institutes | Cancer | Details | |
BMS-794833 | BMS-794833,BMS794833 | Preclinical | Bristol-Myers Squibb | Solid tumours | Details |
EMB-01 | EMB-01 | Phase Ⅱ | EpimAb Biotherapeutics | Solid tumours | Details |
Metatinib Trometamol | BMS-817378; SIM-817378 | Phase Ⅰ | Bristol-Myers Squibb, Simcere | Non small cell lung cancer (NSCLC), Gastric cancer, Metastatic colorectal cancer (CRC), Liver cancer | Details |
[18F]-AH113804 | [18F]-AH113804 | Preclinical | GE Healthcare | Diagnostic agents | Details |
EMD-94283 | EMD-94283 | Phase Ⅰ | Merck Serono | Cancer | Details |
Amivantamab | JNJ-61186372; JNJ-372 | Phase Ⅲ | Genmab, Janssen | Non small cell lung cancer (NSCLC) | Details |
Onartuzumab | OA-5D5; PRO-143966; RG-3638; RO-5490258,OA5D5,PRO143966,RG3638,RO5490258 | Phase Ⅲ | Genentech, Chugai | Non small cell lung cancer (NSCLC), Gastric cancer, Breast cancer, Solid tumours, Colorectal cancer, Hepatocellular carcinoma (HCC), Glioblastoma | Details |
Glumetinib | HH-SCC244; SCC244 | Phase Ⅱ | Shanghai Institute of Materia Medica, Shanghai Green Valley Pharmaceutical, Haihe Biopharma | Non small cell lung cancer (NSCLC) | Details |
SPH3348 | SPH-3348 | Phase Ⅰ | Shanghai Pharma | Gastric cancer, Lung cancer, Liver cancer | Details |
XL-092 | XL-092 | Phase Ⅰ | Exelixis | Cancer | Details |
Sym-015 | Sym-015 | Phase Ⅱ | Symphogen | Lung cancer | Details |
RXDX-106 | RXDX-106 | Phase Ⅰ | Teva, Daiichi Sankyo, Roche | Solid tumours | Details |
AMG-337 | AMG-337,AMG337 | Phase Ⅱ | Amgen, NantPharma, Astellas | Gastric cancer, Esophageal adenocarcinoma, Solid tumours | Details |
Glesatinib | MGCD-265; MG-90265; MG-90265H9; MG-90265X; MG-90265gly; 7Q29OXD98N,MGCD265 | Phase Ⅱ | Mirati Therapeutics | Non small cell lung cancer (NSCLC), Solid tumours | Details |
Recombinant human hepatocyte growth factor (Kyoto University) | Phase Ⅱ | Kyoto University | Liver failure | Details | |
JNJ-38877618 | JNJ-38877618; OMO-1 | Phase Ⅱ | Johnson & Johnson | Solid tumours | Details |
MK-8033 | MK-8033,MK8033 | Phase Ⅰ | Merck Sharp & Dohme | Solid tumours | Details |
c-Met/PD-L1 CAR-T cell (The Second Hospital of Nanjing Medical University) | Phase Ⅰ | The Second Hospital of Nanjing Medical University | Primary hepatocellular carcinoma | Details | |
BPI-9016 | BPI-9016M; BPI-9016 | Phase Ⅰ | Betta | Non small cell lung cancer (NSCLC) | Details |
S-49076 | S-49076,S49076 | Phase Ⅱ | Servier | Non small cell lung cancer (NSCLC), Glioblastoma | Details |
This web search service is supported by Google Inc.